The Rise of the Zombie CEOsBreakout Videos For the second time in as many months, a floundering corporation has gone back to the future by bringing back a … Article source: http://finance.yahoo.com/news/no-childhood-leukemia-found-near-135646153.html
Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online today in Blood, the Journal of the American Society of Hematology (ASH). Acute myeloid leukemia (AML), the second most common form of leukemia in children, is a blood cancer in which the bone marrow makes
(More)…
Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online today in Blood, the Journal of the American Society of Hematology (ASH). Acute myeloid leukemia (AML), the second most common form of leukemia in children, is a blood cancer in which the bone marrow makes
(More)…
DUBLIN–(BUSINESS WIRE)– Research and Markets (http://www.researchandmarkets.com/research/dcx9b3/leukemia) has announced the addition of the “Leukemia Partnering 2007-2013″ report to their offering. The Leukemia Partnering 2007-2013 provides understanding and access to the leukemia partnering deals and agreements entered into by the worlds leading healthcare companies. This data driven report includes: Trends in leukemia dealmaking in the biopharma industry since 2007 Access to summary headline, upfront, milestone and royalty data Access to over 150 leukemia contract documents The leading
(More)…
DUBLIN–(BUSINESS WIRE)– Research and Markets (http://www.researchandmarkets.com/research/dcx9b3/leukemia) has announced the addition of the “Leukemia Partnering 2007-2013″ report to their offering. The Leukemia Partnering 2007-2013 provides understanding and access to the leukemia partnering deals and agreements entered into by the worlds leading healthcare companies. This data driven report includes: Trends in leukemia dealmaking in the biopharma industry since 2007 Access to summary headline, upfront, milestone and royalty data Access to over 150 leukemia contract documents The leading
(More)…
NEW YORK, May 23, 2013 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue: PharmaPoint: Chronic Myeloid Leukemia (CML) – United States Drug Forecast and Market Analysis to 2022 http://www.reportlinker.com/p01190417/PharmaPoint-Chronic-Myeloid-Leukemia-CML—United-States-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswireutm_medium=prutm_campaign=Pathology PharmaPoint: Chronic Myeloid Leukemia (CML) – United States Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Chronic Myeloid Leukemia (CML) – United States Drug Forecast and Market Analysis to 2022″. Chronic
(More)…
A local teen is fighting to regain his health after being diagnosed with leukemia, and supporters have raised about $60,000 to help pay his and his family’s expenses. An avid basketball player and accomplished sailor, Christopher Williford sported a deep tan from years of being outside and on the water. But in November, David Williford was troubled to see his son, 17 and a junior at St. Thomas Aquinas High School, lose his healthy color.
(More)…
Public release date: 23-May-2013 [ | E-mail | Share ] Contact: Amanda Szaboaszabo@hematology.org 202-552-4914American Society of Hematology (WASHINGTON, May 23, 2013) Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online today in Blood, the Journal of the American Society of Hematology (ASH). Acute myeloid
(More)…
Public release date: 23-May-2013 [ | E-mail | Share ] Contact: Amanda Szaboaszabo@hematology.org 202-552-4914American Society of Hematology (WASHINGTON, May 23, 2013) Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online today in Blood, the Journal of the American Society of Hematology (ASH). Acute myeloid
(More)…
Japan Fuels Global Sell-Off but Wall Street Sharply Pares Earlier LossesBreakout Videos After rising 80% in the past seven months, Japan’s benchmark Nikkei 225 stock index finally blinked. A staggering … Article source: http://finance.yahoo.com/news/japan-chronic-myeloid-leukemia-market-124500560.html